1
Clinical Trials associated with Ad-sig-hMUC-1/ecdCD40L vaccine(Jonsson Comprehensive Cancer Center)A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated metastatic breast cancer.
100 Clinical Results associated with Ad-sig-hMUC-1/ecdCD40L vaccine(Jonsson Comprehensive Cancer Center)
100 Translational Medicine associated with Ad-sig-hMUC-1/ecdCD40L vaccine(Jonsson Comprehensive Cancer Center)
100 Patents (Medical) associated with Ad-sig-hMUC-1/ecdCD40L vaccine(Jonsson Comprehensive Cancer Center)
100 Deals associated with Ad-sig-hMUC-1/ecdCD40L vaccine(Jonsson Comprehensive Cancer Center)